Impact of Pharmacogenetic Testing on Cost Effectiveness in Mental Illness

Phase 2

• Conditions: Major depressive disorder (MDD); schizoaffective disorder; Mental Health - Schizophrenia; Schizophrenia,; bipolar disorder; Mental Health - Other mental health disorders; Mental Health - Depression

• Registration Number: ACTRN12621001222831
• Lead Sponsor: Flinders University of South Australia

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-09-13
• Last Update Posted: 20 September 2021

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 1032

Inclusion Criteria

Adults with a diagnosis of treatment resistant MDD or SSD, both with or without comorbid disorders confirmed by the MINI interview and are taking prescribed psychotropic medications. Treatment resistance is defined as have trialed 2 or more medications with inadequate treatment response for a minimum of 4 months as determined by the patient and psychiatrist and for those with MDD, PHQ-9 >= 10 and for SDD, each item with a score > 3 on PANSS.

Exclusion Criteria

Intellectual or cognitive or language difficulty that prohibits an understanding or participation in the program, active psychosis, severe distress or suicidality, or substance intoxication.

Study & Design

• Study Type: Interventional
• Study Design: Not specified